FXS6837 Capsule

DRUG2 trials

Sponsors

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Conditions

Paroxysmal Nocturnal HemoglobinuriaPrimary IgAN

Phase 2

FXS6837 for the Treatment for IgAN Patients（Longterm Study）

Not yet recruitingNCT07750665

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Primary IgAN

Start: 2026-09-30End: 2030-01-04Target: 60Updated: 2026-08-06

Phase 3

A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.

Not yet recruitingNCT07747090

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Paroxysmal Nocturnal Hemoglobinuria

Start: 2026-12-10End: 2028-07-31Target: 90Updated: 2026-08-05